Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 7/20 | 0.51 |
| ▸ | MAOA | P21397 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742556 | 0.90 | HRH3 (0.54) | HRH3ALDH2PDK1PDK2BCHE | |
| SCHEMBL4745671 | 0.89 | PDK1 (0.60) | HRH3ALDH2PDK1PDK2BCHE | |
| SCHEMBL4741928 | 0.89 | HRH3 (0.54) | HRH3ALDH2PDK1PDK2BCHE | |
| SCHEMBL4745128 | 0.89 | HRH3 (0.54) | HRH3ALDH2MAOAMAOBPDK1 | |
| SCHEMBL4742644 | 0.88 | HRH3 (0.52) | HRH3ALDH2PDK1PDK2BCHE | |
| SCHEMBL4746388 | 0.88 | HRH3 (0.54) | HRH3ALDH2PDK1PDK2BCHE | |
| SCHEMBL4744107 | 0.87 | HRH3 (0.51) | HRH3ALDH2MAOAMAOBPDK1 | |
| SCHEMBL4745561 | 0.87 | HRH3 (0.53) | HRH3PDK1PDK2BCHEACHE | |
| SCHEMBL4742617 | 0.87 | HRH3 (0.53) | HRH3PDK1PDK2BCHEACHE | |
| SCHEMBL4742594 | 0.86 | HRH3 (0.56) | HRH3MAOBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008107321-A1 | HETEROCYCLIC COMPOUNDS USED AS ANTI-NEOPLASIC AGENTS OR CELL PROLIFERATION INHIBITORS | CEREP (FR) | 2008-09-12 | — | — | WO | disclosed |